

**CSK Antibody (N-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP13748a****Specification**

---

**CSK Antibody (N-term) Blocking peptide - Product Information**Primary Accession [P41240](#)**CSK Antibody (N-term) Blocking peptide - Additional Information****Gene ID** 1445**Other Names**

Tyrosine-protein kinase CSK, C-Src kinase, Protein-tyrosine kinase CYL, CSK

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13748a was selected from the N-term region of CSK. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**CSK Antibody (N-term) Blocking peptide - Protein Information****Name** CSK**Function**

Non-receptor tyrosine-protein kinase that plays an important role in the regulation of cell growth, differentiation, migration and immune response. Phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs) including LCK, SRC, HCK, FYN, LYN, CSK or YES1. Upon tail phosphorylation, Src-family members engage in intramolecular interactions between the phosphotyrosine tail and the SH2 domain that result in an inactive conformation. To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. Suppresses signaling by various surface receptors, including T-cell receptor (TCR) and B-cell receptor (BCR) by phosphorylating and maintaining inactive several positive effectors such as FYN or LCK.

**Cellular Location**

Cytoplasm. Cell membrane. Note=Mainly cytoplasmic, also present in lipid rafts

**Tissue Location**

Expressed in lung and macrophages.

**CSK Antibody (N-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**CSK Antibody (N-term) Blocking peptide - Images****CSK Antibody (N-term) Blocking peptide - Background**

Specifically phosphorylates 'Tyr-504' on LCK, which acts as a negative regulatory site. Can also act on the LYN and FYN kinases.

**CSK Antibody (N-term) Blocking peptide - References**

Niu, W., et al. Clin. Chim. Acta 411 (19-20), 1491-1495 (2010) :Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Liu, C.Y., et al. Carcinogenesis 31(7):1259-1263(2010)Mikkola, E.T., et al. J. Mol. Biol. 399(4):618-627(2010)Takeuchi, F., et al. Circulation 121(21):2302-2309(2010)